Hexima Limited announced that Geoffrey Kempler has been appointed as the new Chairman of the Company to lead the future direction of the Company. Mr. Kempler is Chairman of AusBiotech and Chairman and Founder of ASX-listed Alterity Therapeutics Limited. He is a qualified psychologist with extensive experience in investment and business development.

Appointment Date is 05 September 2023. Mr. Kempler was appointed following the completion of the process initiated by the Company to identify and appoint a new Chairman following the recent passing of the Company's former Chairman, Professor Jonathan West. As part of the Board restructure, the Company's US based directors, Michael Aldridge, Scott Robertson and Jake Nunn have resigned as Non-Executive Directors of the Company.

Mr. Aldridge was appointed as a director in May 2019 and served as the Company's CEO between September 2020 and August 2022. His extensive biopharmaceutical experience was of great assistance while the Company was actively pursuing the development of a potential onychomycosis treatment. Mr. Robertson was appointed as a director in November 2018 and brought to the Company significant experience in crop genetics and agriculture based M&A activity and investment.

Mr. Nunn was appointed as a director in September 2021, assisting the Company with his extensive knowledge and skills in financing and strategic growth of biotechnology companies. Following the disappointing results from the Company's clinical trial of its potential treatment, Messrs Aldridge, Robertson and Nunn remained as Directors to assist with the formulation of a new direction for the Company. They did so without seeking to be remunerated for that continuing role.

With the appointment of a new Chairman to lead the future direction of the Company, Messrs Aldridge, Robertson and Nunn considered it was now an appropriate time for them to offer their resignations.